OGN
OrganonANYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The pending all-cash Sun Pharma deal gives the stock a clear cash takeout anchor, and Q1 showed enough profitability to keep the business stable while approvals work through. The available target summary is incomplete, but the reported median target of $9.67 is less relevant than the merger consideration itself.
Posture
Constructive
Lead driver
Momentum
What changed
1 setup hits (3d) with net bearish as of 2026-06-02.
What can break
Debt remains materially larger than cash, which limits the standalone rerating case and increases downside if the merger path changes.
Momentum
98
Value
70
Sentiment
45
Setup hits (3d)
1 · Net Bearish
AI TargetsBase $13.60 · Bull $14.00 · Bear $9.50
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-29 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Bearish
Target $9.67
Why
Momentum98 · Δ7d -1.8
Value70 · Δ7d +0.3
Sentiment45 · Δ7d +0.8
So what
Strength-led posture (Net Bearish). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
98
34% active weight
Current posture
7d trendSoftening
Δ7d
-1.8
Δ21d
-1.6
Value
70
32% active weight
Current posture
7d trendFlat
Δ7d
+0.3
Δ21d
+0.4
Sentiment
45
33% active weight
Current posture
7d trendFlat
Δ7d
+0.8
Δ21d
+4.8
Why this grade
Composite grade A. Momentum 97.7 / Value 70.0 / Sentiment 45.4
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$3.51B
Beta
0.54
Shares Out
259.98M
P/E (TTM)
3.9
P/S (TTM)
0.31
P/FCF (TTM)
4.74
Rev YoY
+1.3%
EPS YoY
-55.6%
Gross Margin
+55.0%
Op Margin
+11.1%
Net Debt
$8.21B
Current Ratio
1.75
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology